Skip to main content
Clinical Trials/NCT04224896
NCT04224896CompletedNot Applicable

Narrow-Band Imaging (NBI) Versus Lugol Chromoendoscopy in the Detection of Oesophagus Squamous Cell Carcinoma in High Risk Population: a Randomised Controlled Multicentre Trial

Hôpital Edouard Herriot0 sites335 target enrollmentStarted: March 1, 2011Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
335
Primary Endpoint
SPECIFICITY OF THE TWO DIAGNOSTIC STRATEGIES

Study Overview

Brief Summary

Narrow-Band Imaging (NBI) is as sensitive as Lugol chromoendoscopy to detect oesophageal squamous cell carcinoma (SCC) and appears more specific than Lugol chromoendoscopy in expert centres but its specificity in current practice is not known. This study aimed to prove the superiority of NBI specificity over Lugol chromoendoscopy to detect oesophageal SCC and high-grade dysplasia (HGD) in current practice (including tertiary care centres, local hospitals and private clinics).

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Patients had a history or current SCC

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

SPECIFICITY OF THE TWO DIAGNOSTIC STRATEGIES

Time Frame: 4 years

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jean Christophe Saurin

Professor

Hôpital Edouard Herriot

Similar Trials